Telomir Pharmaceuticals, Inc. has announced that its S-3 registration statement has become effective as of November 5, 2026. This filing allows the company to raise capital by selling securities, which is crucial for its growth and operational strategies.

Telomir Pharmaceuticals is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol TELO. As an emerging growth company based in Miami, Florida, Telomir focuses on developing innovative pharmaceutical solutions.

The filing states, "The effectiveness date for the registration statement is November 5, 2026." This indicates that the company is now authorized to proceed with its capital-raising efforts.

This development may impact investors, stakeholders, and competitors within the pharmaceutical preparations industry. The ability to raise funds through the sale of securities can enhance Telomir's financial stability and support its research and development initiatives.

The filing does not say what happens next.

Company Information

Telomir Pharmaceuticals, Inc. is incorporated in Florida and operates under the Central Index Key (CIK) number 0001971532. The company has a fiscal year that ends on December 31st, which is important for investors to note when analyzing financial statements and performance metrics.

The business address for Telomir is located at 100 SE 2nd St, Suite 2000 #1009, Miami, FL 33131. This central location may provide strategic advantages in terms of access to key markets and resources within the pharmaceutical industry.

Filing Details

The registration statement filed under SEC Form S-3 is associated with the Securities Act of 1933, specifically under file number 333-299654. This form is typically used by companies that meet certain criteria to streamline the process of raising capital.

The filing indicates that the effectiveness date for the registration statement is November 5, 2026, at 4:00 PM, which is a critical timestamp for regulatory compliance and investor awareness.

As of the filing date, the document does not specify the amount of capital Telomir Pharmaceuticals intends to raise or the specific securities that will be offered for sale. Additionally, there is no information regarding potential use of proceeds from the capital raise, which is often a key consideration for investors.